CNS vs INDV: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
CNS and INDV are similarly sized, but INDV trades noticeably cheaper on forward earnings (6.65x vs 18.57x): the market is paying up for CNS's profile and pricing INDV more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CNS vs INDV: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNS | INDV | What it tells you |
|---|---|---|---|
| Market cap | $3.58B | $3.83B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.57 | 6.65 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 21.42 | 11.63 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Price vs 52-week range | 40% of range | 46% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: INDV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CNS and INDV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and INDV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and INDV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT), which in October 2026 bought the Manchester Village Shopping Center in Rock Hill, South Carolina.
What does Indivior (INDV) do?
Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. Its flagship product, SUBLOCADE, is a once-monthly long-acting injectable form of buprenorphine that has become the dominant long-acting injectable (LAI) for OUD in the United States, holding roughly a 76% share of that market. The company also sells the sublingual film SUBOXONE (now facing generic competition), the opioid overdose reversal agent OPVEE (nalmefene nasal spray), and PERSERIS for schizophrenia. Indivior historically listed in London but shifted its primary listing to the Nasdaq, and it trades under the ticker INDV.
CNS vs INDV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNS drivers: Interest rates and real assets; Return to organic growth.
- INDV drivers: SUBLOCADE market leadership and expansion; Margin expansion and cash generation.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For INDV, indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company.
CNS or INDV: which should you pick?
CNS vs INDV: the full fundamentals
CNS. As of mid-October 2026, CNS trades at about 21 times trailing and 19 times forward earnings with a dividend yield near 3.9%, a little cheaper than in the spring after the shares pulled back from their 52-week high of about $86.56. The third quarter showed revenue growth holding at about 11% with margins intact, so the debate is less about the quarter and more about whether higher bond yields keep pressing on AUM. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
INDV. Indivior trades as a profitable mid-cap specialty pharma at about 11.8x trailing and 6.7x forward earnings and roughly 2.9x sales, a lower multiple than in mid-2026 after a pullback of nearly 19% over three months. The $8.13 special dividend, payable only if the Supernus merger closes, equals about a quarter of the October 16 share price, so post-dividend shares will represent a stake in the combined Supernus, Inc. Analysts expect 2026 EPS of about $4.41 and 2027 EPS of about $4.88 on a standalone basis.
Headline figures (approximate, October 2026): CNS shows revenue (ttm) ~$600M, +11% YoY in Q3 2026, revenue (q3 2026) ~$157.4M, adjusted eps (q3 2026) ~$0.89, roughly in line with consensus, net income (ttm) / net margin ~$169M / ~28%; INDV shows revenue (ttm) ~$1.33B, q2 2026 revenue ~$343M (up ~14% YoY), net income (ttm) ~$356M (EPS ~$2.79), margins (gross / operating) ~86% / ~47%.
The bottom line: CNS vs INDV
CNS and INDV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and INDV exposure against your real portfolio. It is not an investment adviser.
Wondering how CNS or INDV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cohen & Steers with AI
Connect the broker you already use and ask Walnut's AI how CNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNS and INDV?
+
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNS or INDV the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNS or INDV?
+
On forward P/E (as of October 2026), CNS trades at 18.57x and INDV at 6.65x, so INDV is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNS and INDV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNS vs INDV?
+
CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time; the AUM declines reported for August and September 2026 show that dynamic at work. EPS has come in slightly below consensus in three of the last four quarters. The dividend absorbs about 79% of trailing earnings, which leaves less cushion if profits dip. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. INDV: Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. The Supernus merger adds its own risks: it may not close if either stockholder vote or another condition fails (in which case the $8.13 special dividend is not paid), integration and the $125 million synergy target may disappoint, and the combined company takes on a $650 million term loan to help fund the $1.0 billion dividend, for pro forma net debt of about $878 million. The stock fell about 19% over the three months to mid-October 2026 as the market weighed these issues. Legacy SUBOXONE film revenue continues to erode as generics take share, and the company has a long history of antitrust and opioid-related litigation and settlements that can resurface as financial and reputational overhangs. Reliance on government and Medicaid channels exposes revenue to reimbursement and budget shifts. Pipeline setbacks, such as the decision to halt INDV-6001 Phase 3, show that non-core bets may not deliver. As a specialty pharma, it also faces regulatory, patent, and manufacturing risks common to the sector.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or INDV; figures are approximate and dated (as of October 2026). Verify current data before investing.